{
    "clinical_study": {
        "@rank": "144867", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating\n      women who have breast cancer that is metastatic or cannot be treated with surgery."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery", 
        "completion_date": {
            "#text": "July 2009", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate in women with locally unresectable or metastatic breast\n           cancer treated with docetaxel, leucovorin calcium, and fluorouracil as second or\n           third-line chemotherapy.\n\n        -  Evaluate the toxic effects of this regimen in these patients.\n\n        -  Determine the time to progression in patients treated with this regimen.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive docetaxel IV over 1 hour on day 1 and leucovorin calcium IV over 1 hour\n      followed by fluorouracil IV over 5 minutes on days 1-3. Treatment repeats every 4 weeks for\n      2-8 courses in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 3 months.\n\n      PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 44\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed breast cancer\n\n               -  Metastatic or unresectable local disease\n\n          -  Measurable or evaluable disease\n\n          -  No ascites or pleural effusion as only metastatic site\n\n          -  No brain or leptomeningeal metastases\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  0-2\n\n        Life expectancy:\n\n          -  At least 3 months\n\n        Hematopoietic:\n\n          -  Granulocyte count greater than 1,500/mm3\n\n          -  Platelet count greater than 100,000/mm3\n\n        Hepatic:\n\n          -  Bilirubin normal\n\n          -  SGOT/SGPT less than 1.5 times upper limit of normal (ULN)\n\n          -  Alkaline phosphatase less than 2.5 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 2 times ULN\n\n        Cardiovascular:\n\n          -  Adequate cardiac function\n\n          -  No history of significant atherosclerotic coronary disease (e.g., uncontrolled\n             angina)\n\n          -  No history of significant cardiac arrhythmia\n\n        Other:\n\n          -  No serious medical or psychiatric illness that would preclude study\n\n          -  No active uncontrolled bacterial, viral, or fungal infection\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior high-dose chemotherapy and autologous transplantation\n\n        Chemotherapy:\n\n          -  At least 3 weeks since prior chemotherapy and recovered\n\n          -  No more than 2 prior chemotherapy regimens for metastatic breast cancer (in addition\n             to adjuvant therapy)\n\n          -  No prior docetaxel\n\n          -  No prior high-dose chemotherapy and autologous transplantation\n\n          -  Prior paclitaxel allowed\n\n        Endocrine therapy:\n\n          -  No concurrent hormonal therapy, except as contraception\n\n        Radiotherapy:\n\n          -  At least 3 weeks since prior radiotherapy and recovered\n\n          -  Concurrent radiotherapy for relief of localized pain or obstruction allowed\n\n        Surgery:\n\n          -  At least 2 weeks since prior major surgery and recovered\n\n        Other:\n\n          -  No other concurrent cytotoxic agents"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00015886", 
            "org_study_id": "CDR0000068567", 
            "secondary_id": [
                "CCCWFU-74896", 
                "NCI-3137"
            ]
        }, 
        "intervention": [
            {
                "description": "75 milligrams per meter squared intraveneously", 
                "intervention_name": "docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "350 milligrams intraveneously", 
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage IV breast cancer", 
            "recurrent breast cancer", 
            "stage IIIB breast cancer"
        ], 
        "lastchanged_date": "July 12, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CCCWFU-74896"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Goldsboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27534"
                    }, 
                    "name": "Southeastern Medical Oncology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27858-4354"
                    }, 
                    "name": "East Carolina University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157-1082"
                    }, 
                    "name": "Comprehensive Cancer Center at Wake Forest University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }, 
                    "name": "Cancer Centers of the Carolinas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29303"
                    }, 
                    "name": "Palmetto Hematology/Oncology Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298-0037"
                    }, 
                    "name": "Massey Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Docetaxel (Taxotere) and 5-Fluorouracil As Second- Or Third-Line Chemotherapy In Women With Metastatic Breast Cancer", 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "Gretchen Kimmick, MD, MS", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To determine the response rate to this combination after two to four courses of Docetaxel (Taxotere) And 5-Fluorouracil", 
            "safety_issue": "No", 
            "time_frame": "28 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00015886"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate toxicities of Docetaxel (Taxotere) And 5-Fluorouracil", 
            "safety_issue": "Yes", 
            "time_frame": "28 weeks"
        }, 
        "source": "Comprehensive Cancer Center of Wake Forest University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Comprehensive Cancer Center of Wake Forest University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1997", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "Cancer Centers of the Carolinas": "34.853 -82.394", 
        "Comprehensive Cancer Center at Wake Forest University": "36.1 -80.244", 
        "East Carolina University School of Medicine": "35.613 -77.366", 
        "Massey Cancer Center": "37.541 -77.436", 
        "Palmetto Hematology/Oncology Associates": "34.95 -81.932", 
        "Southeastern Medical Oncology Center": "35.385 -77.993"
    }
}